Which gives the most weight loss, Wegovy or Mounjaro?
Mounjaro gives the most weight loss on average: 20.2% against 13.7% on Wegovy in the comparison study SURMOUNT-5.
In the SURMOUNT-5 study from 2025, 751 adults with obesity without diabetes were randomly assigned to either Mounjaro or Wegovy for 72 weeks. Waist circumference fell by an average of 18.4 cm on Mounjaro and 13.0 cm on Wegovy. The study was paid for by Eli Lilly, which makes Mounjaro.[1]
SURMOUNT-5: both medicines were given at the highest dose the participants could tolerate.[1]
Wegovy has since gained a higher dose. In the STEP UP study, 7.2 mg gave a weight loss of 18.7% over 72 weeks, against 15.6% on 2.4 mg and 3.9% on placebo (an inactive dummy treatment). The 7.2 mg dose is approved in the EU for adults with a BMI (the ratio between weight and height) of 30 or above.[3][5]
Which is better documented for the heart, Wegovy or Mounjaro?
Wegovy is better documented for the heart: in the SELECT study, Wegovy gave a 20% lower risk of serious cardiovascular events, while Mounjaro's equivalent study is not finished.
In the SELECT study from 2023, 17,604 adults with cardiovascular disease and overweight or obesity, but without diabetes, were given Wegovy 2.4 mg or placebo. They were followed for an average of 39.8 months. Death from cardiovascular disease, heart attack or stroke occurred in 6.5% on Wegovy against 8.0% on placebo.[2]
Mounjaro's equivalent heart study, SURMOUNT-MMO, has 15,374 participants and is not finished. The results are expected at the end of 2027 at the earliest. This does not mean that Mounjaro is worse for the heart, only that it has not yet been studied in the same way.[4]
How does the doctor choose between Wegovy and Mounjaro?
The doctor chooses between Wegovy and Mounjaro based on your health, your other medication, side effects and price.
Both are pens you use once a week. Wegovy mimics the gut hormone GLP-1, while Mounjaro mimics both GLP-1 and GIP. In SURMOUNT-5 the side effects in both groups mostly came from the stomach and gut, were usually mild to moderate and occurred mainly during dose escalation.[1]
Averages do not tell you how you in particular will respond, so the choice is always individual. At Recepta the first doctor consultation is free, and the doctor follows up every 4 weeks.
| Wegovy | Mounjaro | |
|---|---|---|
| Active substance | Semaglutide | Tirzepatide |
| Mimics | GLP-1 | GLP-1 and GIP |
| Weight loss after 72 weeks | 13.7% | 20.2% |
| Waist circumference after 72 weeks | 13.0 cm smaller | 18.4 cm smaller |
| Large heart study without diabetes | Yes, 20% lower risk | Not finished, expected at the end of 2027 at the earliest |
Figures from SURMOUNT-5 and SELECT.[1][2] Current pharmacy prices are in Medication prices in Denmark
Read also: How big is the risk that Wegovy or Mounjaro won't work? · Is Mounjaro available as a pill?
Questions and answers about Wegovy and Mounjaro
Is Mounjaro better than Wegovy for everyone?
How do you take Wegovy and Mounjaro?
What side effects do Wegovy and Mounjaro have?
Sources
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine 2025;393(1):26-36. doi.org
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine 2023;389(24):2221-2232. doi.org
- Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). The Lancet Diabetes & Endocrinology 2025;13(11):949-963. doi.org
- ClinicalTrials.gov: A Study of Tirzepatide on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO), NCT05556512. Updated 12 November 2026. clinicaltrials.gov
- European Medicines Agency (EMA): Summary of product characteristics for Wegovy (semaglutide), section 4.2 on dosing. ema.europa.eu